Skip to Content

Tikosyn (dofetilide) Disease Interactions

There are 5 disease interactions with Tikosyn (dofetilide):

Major

Dofetilide (applies to Tikosyn) long QT interval

Major Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome

Dofetilide is contraindicated in patients with congenital or acquired long QT syndromes. Dofetilide should not be used in patients with a baseline QT interval of QTc >440 msec (500 msec in patients with ventricular conduction abnormalities).

Major

Dofetilide (applies to Tikosyn) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Dofetilide is contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 mL/min). The risk of QT interval prolongation, Torsade de Pointes, and ventricular arrhythmias is directly related to dofetilide plasma concentration. A reduced creatinine clearance will increase dofetilide plasma concentration. In patients with mild and moderate renal impairment, the risk of arrhythmias can be reduced by controlling the plasma concentration through adjustment of the initial dofetilide dose according to creatinine clearance. Patients undergoing dialysis were not included in clinical studies, and appropriate dosing recommendations for these patients are unknown. There is no information about the effectiveness of hemodialysis in removing dofetilide from plasma.

Moderate

Dofetilide (applies to Tikosyn) electrolyte imbalance

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diarrhea, Vomiting, Dehydration, Electrolyte Abnormalities

Dofetilide should be avoided in patients that experience symptoms that may be associated with altered electrolyte balance, such as excessive or prolonged diarrhea, sweating, or vomiting or loss of appetite or thirst, these conditions should immediately be reported to their health care provider.

Moderate

Dofetilide (applies to Tikosyn) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Dofetilide has not been studied in patients with severe hepatic impairment. Dofetilide should be used with particular caution in these patients.

Moderate

Dofetilide (applies to Tikosyn) hypokalemia

Moderate Potential Hazard, Moderate plausibility.

Serum potassium should be maintained within the normal range before dofetilide treatment is initiated and should be maintained within the normal range while the patient remains on dofetilide therapy. In clinical trials, potassium levels were generally maintained above 3.6 to 4.0 mEq/L. Exercise care when using this agent in patients with hypokalemia.

Tikosyn (dofetilide) drug interactions

There are 379 drug interactions with Tikosyn (dofetilide)

Tikosyn (dofetilide) alcohol/food interactions

There is 1 alcohol/food interaction with Tikosyn (dofetilide)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.